Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 9Setmelanotide literaturebiorxiv-preprint · Observational2025

Inversed impaired osteogenic activity in children with severe obesity due to MC4R deficiency compared to LEP and LEPR deficiency

Children with MC4R deficiency show higher bone formation markers compared to those with LEP and LEPR deficiencies, indicating differing impacts of genetic obesity on bone health.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the setmelanotide corpus
1
Preclinical
6
Observational · this one
0
Open-label
1
Randomised
1
Reviews

Summary and findings

This study measured bone turnover and metabolic biomarkers in children with severe obesity due to biallelic loss-of-function variants in the LEP, LEPR, or MC4R genes. A total of 41 children with severe obesity and 28 age-matched controls were included. Significant differences in serum levels of osteocalcin and osteopontin were observed among the groups.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Serum osteocalcin and osteopontin levels were significantly lower in subjects with LEP and LEPR biallelic variants compared to controls, p<0.001.2025

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>OBJECTIVE</bold> Chronic obesity is associated with impaired bone health. However, few investigations have been conducted to assess bone physiology in early-onset obesity. In this study, we measured specific bone turnover and metabolic biomarkers in children with severe obesity with biallelic loss-of-function variants of the leptin ( <italic>LEP)</italic> , leptin receptor <italic>(LEPR)</italic> , or melanocortin 4 receptor ( <italic>MC4R)</italic> genes. <bold>METHODS</bold> Forty-one children aged 0.3–13 years with a BMI SDS ≥ 3, previously identified with pathogenic variants in <italic>LEP</italic> , <italic>LEPR</italic> , or <italic>MC4R</italic> , were recruited for the current study. Additionally, 13 age-matched children with severe obesity who tested negative for variants in known obesity-related genes were included, and another 15 unrelated age-matched children with normal body weight served as the control group. Serum osteocalcin, osteopontin, osteoprotegerin, and sclerostin levels were assessed using multi-analyte profiling. Serum leptin, insulin, and cortisol levels were determined using ELISA. <bold>RESULTS</bold> Serum levels of osteocalcin and osteopontin, specific markers of bone formation, were significantly lower in subjects with <italic>LEP</italic> and <italic>LEPR</italic> biallelic variants than in the control group. In contrast, the values of these two biomarkers in subjects with <italic>MC4R</italic> deficiency were significantly higher than those in the other groups. No differences were observed in the bone resorption markers osteoprotegerin and sclerostin. Hyperleptinemia was more pronounced in subjects with <italic>LEPR</italic> deficiency. Serum insulin concentrations were elevated in subjects with <italic>MC4R</italic> deficiency, whereas serum cortisol levels were significantly higher in subjects with <italic>LEP</italic> deficiency than in all other groups. <bold>CONCLUSION</bold> Our data demonstrate that osteogenic activity (but not resorption activity) is differentially affected in children with complete genetic disruption of the leptin signaling pathway. Children with <italic>MC4R</italic> deficiency showed higher osteogenic markers, but children with <italic>LEP</italic> and <italic>LEPR</italic> deficiencies showed the opposite. Our results support the usefulness of bone turnover biomarkers for the assessment and management of bone health in different types of obesity. </p>

Elsewhere in the Setmelanotide corpus

BHuman HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamusbiorxiv-preprint · 2023 · 182 neuronal clusters significantly enriched in expression of BMI GWAS genes.HumanASetmelanotide for the Treatment of Acquired Hypothalamic Obesity.The New England journal of medicine · 2023 · n=120 · LSM change in BMI at 52 weeks was -16.5% (95% CI, -19.3 to -13.8) with setmelanotide and 3.3% (95% CI, -0.6 to 7.2) with placebo (P<0.001)HumanARespiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.Annals of the American Thoracic Society · 2023 · n=123 · Nasopharyngitis incidence ranged from 4.1% (95% CI: 0.7%, 9.3%; tirzepatide, 0-6 months) to over 23.7% (95% CI: 19.6%, 28.1%; liraglutide, 13-24 months).HumanBDevelopmental Trajectories of Autistic Social Traits in Youth Born Extremely Preterm.Journal of the American Academy of Child and Adolescent Psychiatry · 2025 · n=527 · ASTs in EP youth increased an average of 19 raw points from age 10 to 17 years.HumanBRisk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists.Diabetes, obesity & metabolism · 2023 · n=68536 · RR: 0.45; 95% CI, 0.40-0.50 for cataract risk at 5 years.HumanBMelanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide.The Journal of clinical endocrinology and metabolism · 2023 · n=58 · BMI reduction of 3.1 kg/m² after 6 months, n=58, p<0.001.Human